Eli Lilly’s migraine treatment was approved by the US FDA, closely following a positive CHMP opinion, and will potentially be made available without cost for the first year.
As Nordic Life Science Days draws to a close for 2018, so too do the conference ‘super sessions’, covering patient engagement, precision medicine, drug delivery and immune-oncology.
Biopharma-Reporter is on the ground, bringing you the...
BioProcess International has kicked off at Biotech Week Boston. BioPharma-Reporter is here to cover the best of the sessions and the reactions from everyone present.
China’s authorities’ condemnation of Changsheng Biotechnology, after it was found to have falsified data regarding a rabies virus, has caused public concern over the domestic vaccine market.
President Trump’s immigration travel ban will deny pharmaceutical companies the opportunity to hire the ‘best and brightest,’ says Massachusetts Biotechnology Council CEO.
Sanofi will support development of polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies through the expansion of its R&D plant in Chengdu, Sichuan province, China.
The CMO says adding the single-use offering from ABEC will make the newly opened biomanufacturing site in China comparable to stainless steel for commercial mAb production.
BeiGene’s tislelizumab will be the first commercial product to be made from Boehringer-Ingelheim’s site in Shanghai, and the first to be made by a foreign CMO in China.
